LD50 values for doxorubicin, prednisone, and methotrexate in 697 cells cultured with or without MSCs (suspension) in combination or not with the LD50 dose of the hERG1 inhibitor E4031 in B-ALL*
| . | Suspension . | ΜSC . |
|---|---|---|
| Doxorubicin | 0.13 ± 0.04 μg/mL | 0.42 ± 0.06 μg/mL |
| Doxorubicin + E4031 | 0.08 ± 0.04 μg/mL | 0.05 ± 0.01 μg/mL |
| Prednisone | 4.96 ± 1.01 μΜ | 23.82 ± 8.63 μΜ |
| Prednisone + E4031 | 3.77 ± 0.93 μΜ | 3.48 ± 0.97 μΜ |
| Μethotrexate | 2.16 ± 1.33 μΜ | 15.04 ± 2.56 μΜ |
| Μethotrexate + E4031 | 1.20 ± 0.09 μΜ | 2.12 ± 0.65 μΜ |
| E4031 | 22.01 ± 2.34 μΜ | 75.32 ± 5.68 μΜ |
| Roscovitine | 29.13 ± 3.67 μΜ | 34.57 ± 3.51 μΜ |
| . | Suspension . | ΜSC . |
|---|---|---|
| Doxorubicin | 0.13 ± 0.04 μg/mL | 0.42 ± 0.06 μg/mL |
| Doxorubicin + E4031 | 0.08 ± 0.04 μg/mL | 0.05 ± 0.01 μg/mL |
| Prednisone | 4.96 ± 1.01 μΜ | 23.82 ± 8.63 μΜ |
| Prednisone + E4031 | 3.77 ± 0.93 μΜ | 3.48 ± 0.97 μΜ |
| Μethotrexate | 2.16 ± 1.33 μΜ | 15.04 ± 2.56 μΜ |
| Μethotrexate + E4031 | 1.20 ± 0.09 μΜ | 2.12 ± 0.65 μΜ |
| E4031 | 22.01 ± 2.34 μΜ | 75.32 ± 5.68 μΜ |
| Roscovitine | 29.13 ± 3.67 μΜ | 34.57 ± 3.51 μΜ |
The 697 cell line was cultured with or without MSCs (suspension) and exposed to increasing concentrations of doxorubicin, prednisone or methotrexate for 48 hours. The percentage of annexin V+/PI− cells was measured. LD50 values were evaluated by nonlinear regression analysis using Origin 6 software (Microcal Software). Original dose-response curves are reported in supplemental Figure 6.